{"id":214240,"date":"2026-08-20T15:57:50","date_gmt":"2026-08-20T10:27:50","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=214240"},"modified":"2026-08-20T15:57:50","modified_gmt":"2026-08-20T10:27:50","slug":"why-remus-pharmaceuticals-ltd-share-price-rise-2026-08-20","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/why-remus-pharmaceuticals-ltd-share-price-rise-2026-08-20\/","title":{"rendered":"Remus Pharmaceuticals Ltd. (REMUS-SM) Share Price Rises 8.06% as Small Cap Stock Enters Top Gainers Today"},"content":{"rendered":"<style id=\"univest-disable-toc\">#ez-toc-container,.ez-toc-container,.lwptoc,.toc_container,.wp-block-rank-math-toc-block{display:none!important}<\/style>\n<p style=\"margin-top:0!important;margin-bottom:0!important;\"><a href=\"https:\/\/univest.in\/stocks\/remus\/remus-pharmaceuticals-ltd-share-price-today\">Remus Pharmaceuticals Ltd.<\/a> Share Price moved higher on 20 August 2026, with the stock trading at Rs 949.8, up Rs 70.85 or 8.06% for the day. With a market capitalisation of Rs 1,053.25 crore, the company stood out in Stock Market Today as a small-cap name that cleared the workflow\u2019s price rise event bar for its market-cap category. The move is significant because it was not just a marginal uptick in the share price; it was a sizeable same-day gain backed by visible trading activity on the NSE.<\/p>\n<p style=\"margin-top:0!important;\">From the supplied data, the stock opened at Rs 883, traded between Rs 879 and Rs 967.05, and remained well above the previous close of Rs 878.95 through the session snapshot used for this article. That intraday range suggests sustained interest rather than a brief isolated print. Turnover came in at Rs 4.5 crore, while traded volume was 47,400 shares on the NSE, keeping Remus Pharmaceuticals Ltd. Stock News in focus among market movers and top gainers today.<\/p>\n<p>The available data confirms the price event, but it does not establish a company-specific catalyst for why the stock is rising today. Even so, the numbers offer enough for meaningful stock analysis. Investors tracking Remus Pharmaceuticals Ltd. Share Price Today can examine how the price action, valuation, profitability and peer positioning fit together. In this Univest review, the emphasis stays on verified data: what happened, how the stock is valued, how it compares with the Trading industry benchmark, and what metrics deserve the closest watch next.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Remus_Pharmaceuticals_Ltd_REMUS-SM_Share_Price_Today_Price_Action_Analysis\"><\/span><strong>Remus Pharmaceuticals Ltd. (REMUS-SM) Share Price Today: Price Action Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Current Price<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 949.8<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Previous Close<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 878.95<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Today&#39;s Change<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">+Rs 70.85 (+8.06%)<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Day Open<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 883<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Day High<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 967.05<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Day Low<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 879<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Current Volume (NSE)<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">47,400<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>NSE Traded Volume<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">47,400<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Combined NSE + BSE Volume<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">47,400<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Turnover<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 4.5 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 1,053.25 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Cap Category<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Small Cap<\/td>\n<\/tr>\n<\/table>\n<p>Remus Pharmaceuticals Ltd. (REMUS-SM) traded at Rs 949.8. versus the previous close of Rs 878.95, a rise of 8.06%. The stock opened at Rs 883, reached Rs 967.05, touched Rs 879. Reported volume was 47,400.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Remus_Pharmaceuticals_Ltd_REMUS-SM_Fundamental_Analysis\"><\/span><strong>Remus Pharmaceuticals Ltd. (REMUS-SM) Fundamental Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 1,053.25 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">28x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.95x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">40.49%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">48.84%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>EPS<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 31.39<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Dividend Yield<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0.11%<\/td>\n<\/tr>\n<\/table>\n<p>Remus Pharmaceuticals Ltd. was valued at a P\/E ratio of 28x, a P\/B ratio of 2.95x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.<\/p>\n<p>Profitability and capital efficiency were represented by ROE of 40.49% and ROCE of 48.84%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.<\/p>\n<p>Per-share and shareholder-return metrics included EPS of Rs 31.39, dividend yield of 0.11%. Dividend yield is a current or historical ratio and does not guarantee future distributions.<\/p>\n<p>Remus Pharmaceuticals Ltd. Fundamental Analysis shows a company that is not only drawing interest because of price action but also carries notable profitability metrics. At the current market cap of Rs 1,053.25 crore, the stock trades at a P\/E ratio of 28 and a P\/B ratio of 2.95, placing valuation in a range that can be compared directly with its industry benchmarks and listed peers.<\/p>\n<p>On profitability, the supplied numbers are strong. Return on equity stands at 40.49%, while return on capital employed is 48.84%. Those are high figures in absolute terms and suggest the business has been generating meaningful returns on shareholder equity and capital employed. For investors reading Remus Pharmaceuticals Ltd. Financial Results through a valuation lens, those returns are important because they help explain why the market may assign a multiple above some lower-return peers.<\/p>\n<p>EPS is Rs 31.39, which indicates the earnings attributable to each share based on the supplied data. When compared with the current share price of Rs 949.8, that supports the stated P\/E ratio of 28. The dividend yield is 0.11, a relatively small historical payout relative to the current stock price, which implies the current investment case in the data is more closely tied to earnings power and market valuation than to income distribution.<\/p>\n<p>From a financial analysis perspective, the combination of a 28 P\/E, 2.95 P\/B, 40.49% ROE and 48.84% ROCE gives Remus Pharmaceuticals Ltd. Share Price a more substantial fundamental context than a price move alone would suggest. It does not prove a fresh catalyst, and Univest is not inferring one from absent disclosures. But it does show that today\u2019s market attention is landing on a company with strong profitability ratios already visible in the supplied figures.<\/p>\n<p>That makes the next layer of analysis especially relevant: whether the Trading industry benchmark and peer set support the view that the stock is expensive, inexpensive or broadly aligned relative to the numbers available.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Sector_and_Industry_Context\"><\/span><strong>Sector and Industry Context<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Metric<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:10px 12px;background:#F7F9FC;\">Value<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Sector<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Trading<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Industry<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Trading<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Scope<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">same industry<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/E Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">28x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">22.02x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Average P\/E<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">109.78x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark P\/E Range<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">0.11x to 7,785.96x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company P\/B Ratio<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.95x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median P\/B<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">1.3x<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">40.49%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">2.08%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">48.84%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median ROCE<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">4.5%<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Company Market Capitalisation<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 1,053.25 crore<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\"><strong>Benchmark Median Market Cap<\/strong><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:10px 12px;\">Rs 46.38 crore<\/td>\n<\/tr>\n<\/table>\n<p>Remus Pharmaceuticals Ltd. (REMUS-SM) is classified under sector: Trading and industry: Trading.<\/p>\n<p>Remus Pharmaceuticals Ltd. (REMUS-SM) has a P\/E ratio of 28x, which is above the benchmark median of 22.02x, a difference of +27.16%. P\/E is a valuation multiple and is not, by itself, a buy or sell signal.<\/p>\n<p>Remus Pharmaceuticals Ltd. (REMUS-SM) has a ROE of 40.49%, which is above the benchmark median of 2.08%, a difference of +1,846.63%. Remus Pharmaceuticals Ltd. (REMUS-SM) has a ROCE of 48.84%, which is above the benchmark median of 4.5%, a difference of +985.33%.<\/p>\n<p>Track today&#8217;s top gainers through the <a href=\"https:\/\/univest.in\/screeners\/top-gainers\">Univest top gainers screener<\/a>. The peer table below provides the company-level comparison.<\/p>\n<p>The sector data places the company inside the Trading industry, and that benchmark helps frame whether today\u2019s interest is only about price action or also about relative fundamentals. Against a same-industry universe of 439 companies, Remus Pharmaceuticals Ltd. shows stronger profitability than the median and average benchmark figures supplied.<\/p>\n<p>The benchmark scope is explicitly the same industry, covering 439 companies. Within that group, the company P\/E of 28 compares with a median P\/E of 22.02 across 323 companies and an average P\/E of 109.78, with a range running from 0.11 to 7,785.96. That places Remus Pharmaceuticals Ltd. Share Price on a valuation multiple above the industry median but far below the industry average, showing how broad the valuation spread is inside the Trading segment.<\/p>\n<p>On book value multiples, the company P\/B of 2.95 compares with a median of 1.3 across 438 companies and an average of 0.62, while the benchmark range extends from -1,160.8 to 383.33. This means the stock is trading above both the median and average P\/B figures in the same-industry set. In isolation that suggests a richer valuation than a typical Trading company, but valuation needs to be read alongside profitability.<\/p>\n<p>That is where the sector comparison becomes more striking. The company ROE of 40.49% is far above the industry median of 2.08% and the average of 8.19% across 436 companies. Its ROCE of 48.84% is also well above the median of 4.5% and average of 4.61% across 436 companies. Market capitalisation is Rs 1,053.25 crore versus an industry median of Rs 46.38 crore and an average of Rs 21,330.78 crore, with the range spanning Rs 1.11 crore to Rs 92,75,252.6 crore. For Univest, that sector picture suggests a company larger than the median peer and materially stronger than the benchmark on return ratios, even as the share price trades at a premium to median valuation levels.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Peer_Comparison\"><\/span><strong>Peer Comparison<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table style=\"width:100%;border-collapse:collapse;margin:16px 0 22px 0;\">\n<tr>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Company<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Symbol<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">Market Cap (Cr)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/E<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">P\/B<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROE (%)<\/th>\n<th style=\"text-align:left;border:1px solid #E3E7EE;padding:8px;background:#F7F9FC;\">ROCE (%)<\/th>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/dgl\/diksha-greens-ltd-share-price-today\"><strong>Diksha Greens Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">DGL<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">92,75,252.6<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">0<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">0<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">-25.83<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">-6.36<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/elitecon\/elitecon-international-ltd-share-price-today\"><strong>Elitecon International Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">ELITECON<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,727.04<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">8.7<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">5.99<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">-1.29<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">-1.22<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/fischer\/fischer-medical-ventures-ltd-share-price-today\"><strong>Fischer Medical Ventures Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">FISCHER<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,665.49<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">91.08<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">5.83<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">0<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">-11.19<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/sirca\/sirca-paints-india-ltd-share-price-today\"><strong>SIRCA Paints India Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">SIRCA<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,514.79<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">37.47<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">5.11<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">12.99<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">17.3<\/td>\n<\/tr>\n<tr>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\"><a href=\"https:\/\/univest.in\/stocks\/confipet\/confidence-petroleum-india-ltd-share-price-today\"><strong>Confidence Petroleum India Ltd.<\/strong><\/a><\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">CONFIPET<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">2,330.67<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">17.9<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">1.63<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">9.89<\/td>\n<td style=\"border:1px solid #E3E7EE;padding:8px;\">12.79<\/td>\n<\/tr>\n<\/table>\n<p>Remus Pharmaceuticals Ltd. (REMUS-SM) has a P\/E ratio of 28x compared with the displayed peer median of 17.9x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 40.49% compares with a peer median of 0% across the companies shown in the table. ROCE stood at 48.84% versus the displayed peer median of -1.22%, providing a capital-efficiency comparison. Remus Pharmaceuticals Ltd. (REMUS-SM) has a market capitalisation of Rs 1,053.25 crore. Among the 5 peers shown, 5 have a larger market capitalisation.<\/p>\n<p>The peer snapshot shows Remus Pharmaceuticals Ltd. in a mixed but interesting position. Its valuation is neither the cheapest nor the most expensive in the listed comparison set, while its profitability ratios stand out positively against many peers. That combination helps explain why the stock can attract attention during today\u2019s rally without relying on an identified corporate trigger.<\/p>\n<p>Among the supplied peers, Elitecon International trades at a P\/E of 8.7 and P\/B of 5.99 with ROE of -1.29% and ROCE of -1.22%, while Fischer Medical Ventures trades at a P\/E of 91.08 and P\/B of 5.83 with ROE of 0% and ROCE of -11.19%. SIRCA Paints India shows a P\/E of 37.47, P\/B of 5.11, ROE of 12.99% and ROCE of 17.3%. Confidence Petroleum India trades at 17.9 times earnings and 1.63 times book with ROE of 9.89% and ROCE of 12.79%. Vintage Coffee &#038; Beverages stands at a P\/E of 28.47 and P\/B of 3.9 with ROE of 3.02% and ROCE of 4.38%.<\/p>\n<p>Against those numbers, Remus Pharmaceuticals Ltd. Share Price appears roughly aligned with Vintage Coffee on earnings multiple, above Confidence Petroleum and Elitecon, but below Fischer Medical Ventures and SIRCA Paints. On P\/B, the company\u2019s 2.95 is lower than Elitecon, Fischer, SIRCA, Vintage and Khazanchi Jewellers at 5.73, but above Confidence Petroleum at 1.63 and Hindware Home Innovation at 2.24.<\/p>\n<p>The biggest relative strength is profitability. Remus Pharmaceuticals reports ROE of 40.49% and ROCE of 48.84%, both comfortably above Elitecon, Fischer, SIRCA, Confidence Petroleum, Vintage Coffee, Khazanchi Jewellers at 12.06% ROE and 7.94% ROCE, Aayush Art And Bullion at -5.74% ROE and -5.54% ROCE, and Creative Newtech at 18.77% ROE and 19.11% ROCE. Hindware Home Innovation is one of the few peers near the company on returns, with ROE of 47.53% and ROCE of 44.69%.<\/p>\n<p>In market-cap terms, Remus Pharmaceuticals at Rs 1,053.25 crore is smaller than the listed peers shown from Rs 1,660.38 crore upward, while Diksha Greens is an extreme outlier at Rs 92,75,252.6 crore despite negative ROE of -25.83% and ROCE of -6.36%. Univest reads this peer set as evidence that the stock\u2019s valuation is not detached from its profitability profile, though it is not a low-multiple name either.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Why_Investors_Are_Watching_Remus_Pharmaceuticals_Ltd\"><\/span><strong>Why Investors Are Watching Remus Pharmaceuticals Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Today\u2019s move has put the stock on the radar because the price action, profitability profile and peer context all offer something concrete to analyse. While the supplied data does not identify a company-specific reason, Remus Pharmaceuticals Ltd. Share Price has become relevant in Stocks in News because the gain was strong enough to qualify within its small-cap category and because the underlying ratios are notable.<\/p>\n<ul>\n<li><strong>Verified price action:<\/strong> the stock rose Rs 70.85, or 8.06%, to Rs 949.8 from Rs 878.95.<\/li>\n<li><strong>Intraday strength:<\/strong> it opened at Rs 883, touched Rs 967.05 and held far above the day low of Rs 879.<\/li>\n<li><strong>Volume backdrop:<\/strong> 47,400 shares changed hands on the NSE with turnover of Rs 4.5 crore.<\/li>\n<li><strong>Fundamental context:<\/strong> P\/E is 28, P\/B is 2.95, ROE is 40.49%, ROCE is 48.84%, EPS is Rs 31.39 and dividend yield is 0.11.<\/li>\n<li><strong>Sector positioning:<\/strong> ROE and ROCE are well above same-industry medians and averages.<\/li>\n<\/ul>\n<p>What investors may monitor next is whether the stock continues to hold closer to the upper end of today\u2019s range, how the current valuation compares with future financial updates, and whether the strong return ratios remain a distinguishing feature versus peers. Univest also notes that <\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"About_Remus_Pharmaceuticals_Ltd\"><\/span><strong>About Remus Pharmaceuticals Ltd.<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the supplied classification, Remus Pharmaceuticals Ltd. operates within the Trading sector and the Trading industry. That means the clearest verified company context available for Remus Pharmaceuticals Ltd. Share Price is its position inside this listed industry basket rather than a longer business profile or segment disclosure.<\/p>\n<p>Even with limited descriptive fields, the market data offers useful context. The company has a market capitalisation of Rs 1,053.25 crore, which places it well above the industry median market cap of Rs 46.38 crore but below several larger listed peers in the comparison set such as Elitecon International, Fischer Medical Ventures, SIRCA Paints India, Confidence Petroleum India, Vintage Coffee &#038; Beverages, Khazanchi Jewellers, Aayush Art And Bullion, Creative Newtech and Hindware Home Innovation.<\/p>\n<p>Its financial profile within this industry is notable for strong return metrics. A ROE of 40.49% and ROCE of 48.84% stand far ahead of the industry median and average supplied for the Trading benchmark. That helps distinguish the company from many peers that either generate lower returns or, in some cases, show negative return ratios. The stock\u2019s P\/E of 28 and P\/B of 2.95 indicate that the market is not valuing it like a distressed or deeply discounted name, but rather assigning a valuation that sits above benchmark medians while remaining far below the most expensive extremes in the broader industry range. For readers following Remus Pharmaceuticals Ltd. Latest News, that combination of price action and relative profitability is the key verified company context available today.<\/p>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Track_Remus_Pharmaceuticals_Ltd_Share_Price_on_Univest\"><\/span><strong>Track Remus Pharmaceuticals Ltd. Share Price on Univest<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Use <a href=\"https:\/\/univest.in\/stocks\/remus\/remus-pharmaceuticals-ltd-share-price-today\">Remus Pharmaceuticals Ltd. (REMUS-SM) live share-price page<\/a>, <a href=\"https:\/\/univest.in\/screeners\/top-gainers\">Univest top gainers screener<\/a>, <a href=\"https:\/\/univest.in\/blogs\">Univest market blogs<\/a> to review live stock data, top gainers lists and related market analysis.<\/p>\n<p>Investors tracking Remus Pharmaceuticals Ltd. Share Price can use Univest to follow live share price moves, day change, market capitalisation and 52-week market context when available. Univest also helps users monitor valuation ratios such as P\/E and P\/B, profitability indicators including ROE and ROCE, and stock analysis metrics that shape day-to-day market interpretation.<\/p>\n<p>For users interested in Remus Pharmaceuticals Ltd. Share Price Today, Univest brings together price updates, market insights, peer context, shareholding pattern data when reported, and broader sector comparisons in one place. That makes it easier to track whether a stock is moving mainly on price action, on changing fundamentals, or within a wider trend across the Indian stock market. For this stock, today\u2019s rise is the headline, but the supporting ratios are just as relevant.<\/p>\n<div style=\"background:#CC0000;border-radius:8px;padding:16px 20px;margin:24px 0;\">\n<p style=\"color:#FFFFFF;font-size:13px;line-height:1.7;margin:0;\"><strong style=\"color:#FFFFFF;\">Disclaimer:<\/strong> Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).<\/p>\n<\/div>\n<h2 class=\"ez-toc-exclude\"><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions\"><\/span><strong>Frequently Asked Questions<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Why_is_Remus_Pharmaceuticals_Ltd_Share_Price_in_focus_today\"><\/span><strong>Why is Remus Pharmaceuticals Ltd. Share Price in focus today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Remus Pharmaceuticals Ltd. Share Price is in focus because the stock rose 8.06% in a single session to Rs 949.8, gaining Rs 70.85 over the previous close of Rs 878.95 and entering the small-cap top gainer conversation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_was_the_latest_Remus_Pharmaceuticals_Ltd_Share_Price_Today\"><\/span><strong>What was the latest Remus Pharmaceuticals Ltd. Share Price Today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The latest supplied Remus Pharmaceuticals Ltd. Share Price Today was Rs 949.8. At that level, the stock was up 8.06% for the day, after opening at Rs 883 and trading within an intraday range of Rs 879 to Rs 967.05.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_much_did_Remus_Pharmaceuticals_Ltd_rise_today\"><\/span><strong>How much did Remus Pharmaceuticals Ltd. rise today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The stock rose Rs 70.85 on the day, which translated into an 8.06% gain. That move came from a previous close of Rs 878.95 to a current price of Rs 949.8 in the supplied market snapshot.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_does_todays_intraday_range_show_for_the_stock\"><\/span><strong>What does today\u2019s intraday range show for the stock?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The intraday range ran from Rs 879 to Rs 967.05 after an opening price of Rs 883. This shows the stock moved sharply higher during the session and was still trading closer to the day\u2019s high than the low.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_market_capitalisation_of_Remus_Pharmaceuticals_Ltd\"><\/span><strong>What is the market capitalisation of Remus Pharmaceuticals Ltd.?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Remus Pharmaceuticals Ltd. had a market capitalisation of Rs 1,053.25 crore in the supplied data. That places it in the Small Cap category and well above the Trading industry median market cap of Rs 46.38 crore.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Remus_Pharmaceuticals_Ltd_expensive_compared_with_its_industry_PE_benchmark\"><\/span><strong>Is Remus Pharmaceuticals Ltd. expensive compared with its industry P\/E benchmark?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The company trades at a P\/E of 28, above the same-industry median of 22.02 but far below the average of 109.78. That suggests valuation is richer than the median benchmark, though not extreme within the wider industry range.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_does_the_company_compare_on_profitability_ratios\"><\/span><strong>How does the company compare on profitability ratios?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Profitability looks strong in the supplied figures. ROE stands at 40.49% and ROCE at 48.84%, both materially above the industry median values of 2.08% and 4.5%, as well as the average benchmark levels.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_fundamental_metrics_investors_are_tracking\"><\/span><strong>What are the key fundamental metrics investors are tracking?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Key supplied fundamentals include a P\/E of 28, P\/B of 2.95, EPS of Rs 31.39, ROE of 40.49%, ROCE of 48.84% and dividend yield of 0.11, giving investors valuation and profitability context for today\u2019s move.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"How_active_was_trading_in_Remus_Pharmaceuticals_Ltd_on_NSE_today\"><\/span><strong>How active was trading in Remus Pharmaceuticals Ltd. on NSE today?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> Trading activity was 47,400 shares on the NSE, which also represented total reported volume in the supplied snapshot. Turnover stood at Rs 4.5 crore, giving the day\u2019s price rise a measurable participation backdrop.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Has_the_supplied_data_identified_a_company-specific_catalyst_for_the_rise\"><\/span><strong>Has the supplied data identified a company-specific catalyst for the rise?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p><strong>Ans.<\/strong> The supplied data confirms the price rise event but does not establish a company-specific catalyst. What is visible instead is a strong one-day gain, active NSE turnover, and profitability metrics that compare well with industry benchmarks.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Remus Pharmaceuticals Ltd. Share Price rises to Rs Rs 949.8. marking a 8.06% rise today. clearing the 8% threshold for Small Cap stocks. Market cap stands at Rs<\/p>\n","protected":false},"author":29,"featured_media":214239,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[],"class_list":["post-214240","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_thumbnail_id":["214239"],"rank_math_title":["Remus Pharmaceuticals Ltd. Share Price Rises 8.06% Today"],"rank_math_description":["Remus Pharmaceuticals Ltd. Share Price rose 8.06% to Rs 949.8. Read price action, valuation, peer comparison and sector analysis for the stock."],"rank_math_focus_keyword":["Remus Pharmaceuticals Ltd. Share Price"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest.in\/blogs-2\/wp-content\/uploads\/2026\/08\/Remus_Pharmaceuticals_Ltd_REMUS_SM_Share_Price_Rises_806_as_Small_Cap_Stock_Enters_Top_Gainers_Today_bullish.png","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/214240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=214240"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/214240\/revisions"}],"predecessor-version":[{"id":214241,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/214240\/revisions\/214241"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/214239"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=214240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=214240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=214240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}